JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Strona główna・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

3.55 -3.27

Buy Sell

Overview

Share price change

24h

Current

Min

3.51

Max

3.69

Key metrics
By Trading Economics
Income	-15M -40M
Sales	8.2M 50M
Profit margin	-80.43
Employees	435
EBITDA	-19M -42M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+8.7% upside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	206M 1.3B
Previous open	6.82
Previous close	3.55

News Sentiment

By Acuity

50%

177 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

2.02 / 2.115 Support & Resistance

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

28 kwi 2026, 23:33 UTC

Hot Stocks

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 kwi 2026, 23:24 UTC

Earnings

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 kwi 2026, 23:15 UTC

Major News Events

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 kwi 2026, 22:46 UTC

Earnings

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 kwi 2026, 22:37 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 kwi 2026, 22:15 UTC

Earnings

Major News Events

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 kwi 2026, 23:31 UTC

Earnings

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 kwi 2026, 23:31 UTC

Earnings

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 kwi 2026, 23:30 UTC

Earnings

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 kwi 2026, 23:30 UTC

Earnings

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 kwi 2026, 23:19 UTC

Market Talk

Earnings

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 kwi 2026, 23:09 UTC

Earnings

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 kwi 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 kwi 2026, 23:01 UTC

Major News Events

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 kwi 2026, 23:01 UTC

Major News Events

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 kwi 2026, 23:01 UTC

Major News Events

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 kwi 2026, 23:01 UTC

Major News Events

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 kwi 2026, 23:01 UTC

Major News Events

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 kwi 2026, 22:51 UTC

Earnings

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 kwi 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 kwi 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 kwi 2026, 22:40 UTC

Market Talk

Major News Events

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 kwi 2026, 22:32 UTC

Earnings

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 kwi 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 kwi 2026, 22:22 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 kwi 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 kwi 2026, 22:14 UTC

Earnings

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 kwi 2026, 22:14 UTC

Earnings

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 kwi 2026, 22:07 UTC

Market Talk

Major News Events

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

8.7% upside

12 Months Forecast

Average 4 USD 8.7%

High 5 USD

Low 3 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

177 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.